Synonym
NCX-6560; NCX 6560; NCX6560
IUPAC/Chemical Name
4-(nitrooxy)butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate
InChi Key
QBBIDMMGINYIJJ-FIRIVFDPSA-N
InChi Code
InChI=1S/C37H42FN3O8/c1-25(2)35-34(37(45)39-29-13-7-4-8-14-29)33(26-11-5-3-6-12-26)36(27-15-17-28(38)18-16-27)40(35)20-19-30(42)23-31(43)24-32(44)48-21-9-10-22-49-41(46)47/h3-8,11-18,25,30-31,42-43H,9-10,19-24H2,1-2H3,(H,39,45)/t30-,31-/m1/s1
SMILES Code
O=C(C1=C(C(C)C)N(CC[C@H](C[C@H](CC(OCCCCO[N+]([O-])=O)=O)O)O)C(C2=CC=C(F)C=C2)=C1C3=CC=CC=C3)NC4=CC=CC=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
675.75
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Momi S, Impagnatiello F, Guzzetta M, Caracchini R, Guglielmini G, Olivieri R, Monopoli A, Gresele P. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol. 2007 Sep 10;570(1-3):115-24. PubMed PMID: 17632098.
2: Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Sci Rep. 2017 Jan 13;7:40461. doi: 10.1038/srep40461. PubMed PMID: 28084470; PubMed Central PMCID: PMC5233977.
3: Baetta R, Granata A, Miglietta D, Oliva F, Arnaboldi L, Bonomo A, Ferri N, Ongini E, Bellosta S, Corsini A. Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc Drugs Ther. 2013 Jun;27(3):211-9. doi: 10.1007/s10557-013-6445-1. PubMed PMID: 23400638.
4: D'Antona G, Mascaro A, Monopoli A, Miglietta D, Ongini E, Bottinelli R. Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice. Muscle Nerve. 2013 Jan;47(1):72-80. doi: 10.1002/mus.23465. PubMed PMID: 23042511.
5: Momi S, Monopoli A, Alberti PF, Falcinelli E, Corazzi T, Conti V, Miglietta D, Ongini E, Minuz P, Gresele P. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res. 2012 Jun 1;94(3):428-38. doi: 10.1093/cvr/cvs100. PubMed PMID: 22362817.
6: Drechsler M, Soehnlein O, Weber C. Nitric oxide-donating statins upgrade the benefits of lipid-lowering in vascular inflammation by desensitizing neutrophil activation: editorial to: "Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol" by R. Baetta et al. Cardiovasc Drugs Ther. 2013 Jun;27(3):183-5. doi: 10.1007/s10557-013-6452-2. PubMed PMID: 23440356.
